237 related articles for article (PubMed ID: 32467324)
1. Inflammation-Induced Abnormal Expression of Self-molecules on Epithelial Cells: Targets for Tumor Immunoprevention.
Jacqueline C; Lee A; Frey N; Minden JS; Finn OJ
Cancer Immunol Res; 2020 Aug; 8(8):1027-1038. PubMed ID: 32467324
[TBL] [Abstract][Full Text] [Related]
2. Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas.
Beatty PL; Finn OJ
Ann N Y Acad Sci; 2013 May; 1284():52-6. PubMed ID: 23651193
[TBL] [Abstract][Full Text] [Related]
3. Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance.
Iheagwara UK; Beatty PL; Van PT; Ross TM; Minden JS; Finn OJ
Cancer Immunol Res; 2014 Mar; 2(3):263-73. PubMed ID: 24778322
[TBL] [Abstract][Full Text] [Related]
4. Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.
Jacqueline C; Finn OJ
Semin Immunol; 2020 Feb; 47():101394. PubMed ID: 32273212
[TBL] [Abstract][Full Text] [Related]
5. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
6. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
7. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.
Okada H; Attanucci J; Giezeman-Smits KM; Brissette-Storkus C; Fellows WK; Gambotto A; Pollack LF; Pogue-Geile K; Lotze MT; Bozik ME; Chambers WH
Cancer Res; 2001 Mar; 61(6):2625-31. PubMed ID: 11289140
[TBL] [Abstract][Full Text] [Related]
8. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine.
Shawler DL; Bartholomew RM; Garrett MA; Trauger RJ; Dorigo O; Van Beveren C; Marchese A; Ferre F; Duffy C; Carlo DJ; Sherman LA; Gold DP; Sobol RE
Clin Exp Immunol; 2002 Jul; 129(1):99-106. PubMed ID: 12100028
[TBL] [Abstract][Full Text] [Related]
9. Overexpressed oncogenic tumor-self antigens.
Bright RK; Bright JD; Byrne JA
Hum Vaccin Immunother; 2014; 10(11):3297-305. PubMed ID: 25483660
[TBL] [Abstract][Full Text] [Related]
10. Tumor antigens as surrogate markers and targets for therapy and vaccines.
Dalgleish A; Pandha H
Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
[TBL] [Abstract][Full Text] [Related]
12. Natural T cell immunity against cancer.
Nagorsen D; Scheibenbogen C; Marincola FM; Letsch A; Keilholz U
Clin Cancer Res; 2003 Oct; 9(12):4296-303. PubMed ID: 14555498
[TBL] [Abstract][Full Text] [Related]
13. Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination.
Pol JG; Bridle BW; Lichty BD
Methods Mol Biol; 2020; 2058():191-211. PubMed ID: 31486039
[TBL] [Abstract][Full Text] [Related]
14. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.
Kimura T; McKolanis JR; Dzubinski LA; Islam K; Potter DM; Salazar AM; Schoen RE; Finn OJ
Cancer Prev Res (Phila); 2013 Jan; 6(1):18-26. PubMed ID: 23248097
[TBL] [Abstract][Full Text] [Related]
15. Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation.
Farkas AM; Finn OJ
Semin Immunol; 2010 Jun; 22(3):125-31. PubMed ID: 20403708
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell lysates as immunogenic sources for cancer vaccine design.
González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
[TBL] [Abstract][Full Text] [Related]
17. Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention.
Chu NJ; Armstrong TD; Jaffee EM
Clin Cancer Res; 2015 Apr; 21(7):1549-57. PubMed ID: 25623216
[TBL] [Abstract][Full Text] [Related]
18. Primary immunoprevention of adult onset cancers by vaccinating against retired tissue-specific self-proteins.
Tuohy VK; Johnson JM; Mazumder S
Semin Immunol; 2020 Feb; 47():101392. PubMed ID: 31926646
[TBL] [Abstract][Full Text] [Related]
19. Vaccines and other immunological approaches for cancer immunoprevention.
Lollini PL; Nicoletti G; Landuzzi L; Cavallo F; Forni G; De Giovanni C; Nanni P
Curr Drug Targets; 2011 Dec; 12(13):1957-73. PubMed ID: 21158706
[TBL] [Abstract][Full Text] [Related]
20. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
